^
    Back
    Association details:
    Biomarker:MYC overexpression + BCL2 overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    EJHaem
    Title:

    Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

    Published date:
    08/30/2022
    Excerpt:
    However, ibrutinib+R-CHOP improved EFS (HR = 0·50, 95% CI: 0.251-1.003) and progression-free survival (PFS; HR = 0.48, 95% CI: 0.228-1.009) versus placebo+R-CHOP in patients aged <60 but not ≥60 years...A numerical trend was seen towards improved EFS and PFS with ibrutinib+R-CHOP versus placebo+R-CHOP in patients with MYC-high/BCL2-high co-expression.
    Secondary therapy:
    R-CHOP
    DOI:
    10.1002/jha2.517
    Trial ID:
    PHOENIX
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASH 2019
    Title:

    Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial

    Published date:
    11/06/2019
    Excerpt:
    In the phase 3, double-blind, placebo (pbo)-controlled PHOENIX trial (NCT01855750)...examined the outcome of the 97 (30.6%) pts < 60 years of age (n = 317) with MYC-high + BCL2-high and observed an improved EFS and OS with IBR + R-CHOP versus pbo + R-CHOP (HR 0.393; 95% CI, 0.198-0.780; p = 0.0056 for EFS; HR 0.191; 95% CI, 0.055-0.666; p = 0.0037 for OS; Figure).
    Secondary therapy:
    R-CHOP
    DOI:
    10.1182/blood-2019-124443
    Trial ID:
    PHOENIX